

## Prof. Yibin Wang's lab, UCLA – Ramino-Bio LTD. visit

Including Technology Transfer, July 15-16<sup>th</sup>, 2019

**Ramino's aim** is to develop a small-molecule compound (SMC) that enhances the BCAA catabolism of subjects with cardiometabolic diseases by targeting BCKDK (=BDK).

**Purpose of visit:** Introduction with Prof. Yibin Wang, his colleagues, his lab, as well as UCLA Technology Development group members, UCLA facilities, Discussion with other project-related members, and Perform technology transfer from Lab to Ramino-Bio including knowledge and data transfer, overview and assessment for studies and planned development program.

### Attendees

**University of California at Los Angeles:** **Prof. Yibin Wang**, Principle Investigator

**C.G.**, Ph.D., Wang's lab

**A.N.**, CEO, and president UCLA Development Group

**E.W.**, Ph.D, BD Technology Development Group

**D.H.**, MD, Director UCLA Human Nutrition/Diabetes program

**O.S.**, MD, PhD Mitochondria Core and Metabolism Theme director

**A.N.**, MD, Cardiovascular Center Heart Failure director

**Shanghai Jiao Tong University**

**Dr. H.S.**, Principal Investigator

**University of Texas Southwestern**

**Prof. D.C.**, principal investigator.

**Dr. R.M.W.**, Associate Professor, D.C.'s lab

**FutuRx / Ramino-Bio LTD.**

**L.K.**, CTO, Ph.D.

**Dorit Cohen-Carmon**, CSO, Ph.D.

## AGENDA

### Monday, July 15th

- |               |                                                                                                                                                                                 |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09:00 – 09:15 | <u>Introduction</u><br>Wang's and C.D.'s Lab staff with Ramino-Bio/ FutuRx                                                                                                      |
| 09:15 – 10:00 | <u>Ramino-Bio Development Plan – Presentation and Q&amp;A</u><br>Dorit Cohen-Carmon<br>Overview including Y-1 milestones, assays to be developed, Hit identification strategies |
| 10:00 – 11:15 | <u>Wang's lab current BCAA studies – Presentation and Q&amp;A</u><br>Dr. H.S. and C.G from Wang's group on BCAA research<br>Dr. Y.W. on Other Research Projects                 |
| 11:15 – 11:30 | Break                                                                                                                                                                           |
| 11:30 – 11:45 | <u>Lab and Animal facility tour including HMDP strains.</u>                                                                                                                     |
| 12:00 – 13:15 | <u>Lunch</u><br>FutuRx / Ramino & lab members                                                                                                                                   |
| 13:15 – 13:45 | Break                                                                                                                                                                           |
| 14:30 – 15:15 | Director UCLA Human Nutrition/Diabetes program – clinical opportunity in cardiometabolic diseases<br>Dr. Z.L., Rehab Center                                                     |
| 15:30 – 16:00 | Mitochondria Core and Metabolism Theme director – mechanisms of action in treating cardiometabolic diseases<br>Dr. O.S., CHS                                                    |
| 16:15 – 16:45 | Heart failure director – Clinical opportunity of treating cardiometabolic diseases<br>TBD (to be confirmed)                                                                     |

### Tuesday, July 16th

09:00 – 12:00

Wang's lab tech transfer to Ramino-Bio

Tech Transfer issues (see table below)

1. Delivery of in-vitro raw data, protocols, experiments & reports
2. Reagents and chemicals handling, storage, processing
3. Delivery of In-vivo protocols and results
4. Discussions with relevant scientists per (1-3).

12:15 – 13:15

Lunch with Technology business group members

13:30 – 15:30

Tech Transfer – continuation.

15:45 – 16:30

A 1:1 meeting Ramino-Bio with Yibin Wang and Dr. H.S.

Discussion on future Lab studies involving Ramino's milestones, especially in-vivo models. Responsibilities, facilities, protocols, materials, specifications, documentation, results, analysis – to be continued in a future meeting.

16:30 – 17:15

Summary, next steps, greetings and farewell

Tech Transfer detailed plan

It is very important to get as much information as possible for failed attempts & directions as for successes. These data are highly valuable in tech transfer from scientists who conducted the studies.

Technology Transfer from the Yibin's Lab to Ramino-Bio will include:

| Task # | Task                                                                  | Execution                                                                                                                                                                                      |
|--------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | <b>Transfer In-vitro protocols, assay qualification and knowledge</b> | Transfer knowledge, protocol guidance, methods, results, enzymatic (biochemical) and cell-based assays, cell lines, readout, including BCAA/ BCKA levels quantification in plasma and tissues. |
| 2      | <b>Materials from the Lab to Ramino-Bio</b>                           | Reagents, materials and cell lines used for in-vitro and n-vivo assays, notes for special handling, storage and preparation.                                                                   |
| 3      | <b>in-vivo results, protocols, workplan</b>                           | Transfer knowledge, ethical requests, protocol guidance, disease models, results, adverse effects, changes needed for company (e.g. metabolic disease mouse models), lessons learned.          |
| 4      | <b>Studies in Lab per workplan</b>                                    | Discuss future plan studies together. Based on results and discussion with scientists & clinicians.                                                                                            |